Drugs / Acla
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05918198 Background | Feb 2023 → Dec 2024 | acute myeloid leukemia | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acla | “Acla 20mg/d × 4d” NCT05918198 ↗ |